Literature DB >> 14579073

Nd-YAG laser core-through urethrotomy in obliterative posttraumatic urethral strictures in children.

P N Dogra1, G Nabi.   

Abstract

This study analysed the feasibility and effectiveness of Nd-YAG laser core-through urethrotomy in the management of obliterative posttraumatic urethral strictures in children. Between May 1997 and April 2000, 61 patients underwent core-through urethrotomy in posttraumatic urethral strictures, ten of whom were children (ages 5-15 years). Three patients had had previous railroading procedures, two attempted core-through urethrotomy, and two underwent end-to-end urethroplasties. Patients were on suprapubic cystostomy for a mean period of 12 months with mean stricture length of 2 cm. Nd-YAG laser core-through urethrotomy was carried out using 600- micro m bare-contact fibre as a day care procedure. There were no intraoperative or postoperative complications. Micturating cystourethrography was performed 6 weeks following urethral catheter removal. Urethroscopy and uroflowmetry were carried out after 3 months. Mean follow-up was 24 months.Nd-YAG laser core-through urethrotomy was seen to be successful in all patients without any complications. All patients are voiding without obstructive symptoms. Four required optical urethrotomy/endoscopic dilatation at least twice. Nd-YAG laser core-through urethrotomy is a safe and effective procedure for the management of obliterative posttraumatic urethral strictures in children

Entities:  

Mesh:

Year:  2003        PMID: 14579073     DOI: 10.1007/s00383-003-0991-8

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  13 in total

1.  Core through urethrotomy with the neodymium:YAG laser for posttraumatic obliterative strictures of the bulbomembranous urethra.

Authors:  P N Dogra; M Aron; T P Rajeev
Journal:  J Urol       Date:  1999-01       Impact factor: 7.450

2.  Reconstruction of posterior urethral disruption injuries: outcome analysis in 82 patients.

Authors:  A F Morey; J W McAninch
Journal:  J Urol       Date:  1997-02       Impact factor: 7.450

3.  Endoscopic treatment of posterior urethral obliteration: long-term followup and comparison with transpubic urethroplasty.

Authors:  R K Chiou; R Gonzalez; S Ortlip; E E Fraley
Journal:  J Urol       Date:  1988-09       Impact factor: 7.450

4.  Posttraumatic posterior urethral strictures in children: a 20-year experience.

Authors:  M M Koraitim
Journal:  J Urol       Date:  1997-02       Impact factor: 7.450

Review 5.  Pelvic fracture urethral injuries: evaluation of various methods of management.

Authors:  M M Koraitim
Journal:  J Urol       Date:  1996-10       Impact factor: 7.450

6.  Endoscopic treatment of posttraumatic urethral obliteration: experience in 396 patients.

Authors:  S A el-Abd
Journal:  J Urol       Date:  1995-01       Impact factor: 7.450

7.  Prostatomembranous urethral disruptions: management by suprapubic cystostomy and delayed urethroplasty.

Authors:  D A Husmann; W T Wilson; T B Boone; T D Allen
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

8.  Use of the perineal and perineal-abdominal (transpubic) approach for delayed management of pelvic fracture urethral obliterative strictures in children: long-term outcome.

Authors:  M L Podestá
Journal:  J Urol       Date:  1998-07       Impact factor: 7.450

9.  Analysis of factors contributing to success or failure of 1-stage urethroplasty for urethral stricture disease.

Authors:  C G Roehrborn; J D McConnell
Journal:  J Urol       Date:  1994-04       Impact factor: 7.450

10.  Management of posterior urethral strictures secondary to pelvic fractures in children.

Authors:  M A al-Rifaei; S Gaafar; M Abdel-Rahman
Journal:  J Urol       Date:  1991-02       Impact factor: 7.450

View more
  1 in total

1.  Comparison of treatment results between holmium laser endourethrotomy and optical internal urethrotomy for urethral stricture.

Authors:  Slawomir A Dutkiewicz; Mariusz Wroblewski
Journal:  Int Urol Nephrol       Date:  2011-11-30       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.